Cytosorbents Corp 4
4 · Cytosorbents Corp · Filed Aug 28, 2014
Insider Transaction Report
Form 4
Gunton James T.
Director
Transactions
- Conversion
Common Stock
2014-08-18+3,106,988→ 3,106,988 total(indirect: By Partnership) - Sale
Common Stock
2014-08-26$0.24/sh−1,000,000$240,400→ 2,106,988 total(indirect: By Partnership) - Sale
Common Stock
2014-08-27$0.24/sh−360,000$87,876→ 1,746,988 total(indirect: By Partnership) - Conversion
Series B Convertible Preferred Stock
2014-08-18−1,124.73→ 39,091.34 total(indirect: By Partnership)→ Common Stock (3,106,988 underlying)
Footnotes (5)
- [F1]Each share of Series B Preferred Stock has a stated value of $100.00, is convertible at the holder's option into that number of shares of Common Stock equal to the Series B stated value at a conversion price of $0.0362, and has no expiration date.
- [F2]These securities are held directly by NJTC Investment Fund, LP, of which the Reporting Person is a partner. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or any other purpose.
- [F3]The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $0.237 to $0.25.
- [F4]The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
- [F5]The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $0.24 to $0.25.